

## Supplementary Online Content

Hirji S, McGurk S, Kiehm S, et al. Utility of 90-day mortality vs 30-day mortality as a quality metric for transcatheter and surgical aortic valve replacement outcomes. *JAMA Cardiol*. Published online December 18, 2019. doi:0.1001/jamacardio.2019.4657

**eTable 1.** International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM) Codes Used to Identify Procedures and Patient Covariates for This Study

**eTable 2.** Characteristics and Outcomes of Surgical AVR Patients Stratified by 30-Day Mortality Hospital Performance Ranking

**eTable 3.** Characteristics and Outcomes of Transcatheter AVR Patients at Hospitals Which Changed Mortality Performance Rankings From 30 Days to 90 Days

**eTable 4.** Characteristics and Outcomes of Surgical AVR Patients at Hospitals Which Changed Mortality Performance Rankings From 30-Days to 90 Days

**eTable 5.** Changes in Percentile Ranking From 30-Day Mortality to 90-Day Mortality Through Median Shift in Continuous Rank

**eTable 6.** Mean Postoperative Hospital Mortality at 90 Days and 1 Year for Transcatheter and Surgical AVR Stratified by 30-Day Mortality Performance Groups

**eFigure 1.** Study Consort Diagram

**eFigure 2.** Changes in Hospital Performance Rankings at 90 Days and 1 Year Stratified by Risk-Adjusted 30-Day Mortality for Transcatheter AVR and Surgical AVR

**eFigure 3.** Distribution of Causes of Death for Transcatheter AVR and Surgical AVR Patients at 30 Days, 90 Days, and 1 Year

**eFigure 4.** The Hazard (Risk of Mortality) After Both Transcatheter AVR and Surgical AVR

This supplementary material has been provided by the authors to give readers additional information about their work.

**eTable 1: International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM) codes used to identify procedures and patient covariates for this study.**

<b>INCLUSION CRITERIA</b>	
<b>Surgical aortic valve replacement</b>	ICD-9: 35.20, 35.21, 35.22; ICD-10: 02RF07Z, 02RF08Z, 02RF0JZ and 02RF0KZ
<b>Transcatheter aortic valve replacement</b>	ICD-9: 35.05, 35.06 ICD-10: 02RF37Z, 02RF38Z, 02RF3JZ, 02RF3KZ, 02RF37H, 02RF38H, 02RF3JH, 02RF3KH
<b>COVARIATES</b>	
<b>Dyslipidemia</b>	ICD-9: 272.4 ICD-10: E78.4, E78.5
<b>Hypertension,</b>	ICD-9: 401.x, 402.x ICD-10: I10, I11.0, I11.9
<b>Diabetes mellitus</b>	ICD-9: 250.0-250.3, 250.8, 250.9 ICD-10: E10.0, E10.1, E10.6, E10.8, E10.9, E11.0, E11.1, E11.6, E11.8, E11.9, E12.0, E12.1, E12.6, E12.8, E12.9, E13.0, E13.1, E13.6, E13.8, E13.9, E14.0, E14.1, E14.6, E14.8, E14.9
<b>Diabetes mellitus with chronic complications</b>	ICD-9: 250.4-250.7 ICD-10: E10.2-E10.5, E10.7, E11.2-E11.5, E11.7, E12.2-E12.5, E12.7, E13.2-E13.5, E13.7, E14.2-E14.5, E14.7
<b>Peripheral vascular disease</b>	ICD-9: 093.0, 437.3, 440.x, 441.x, 443.1-443.9, 447.1, 557.1, 557.9, V43.4 ICD-10: I70.x, I71.x, I73.1, I73.8, I73.9, I77.1, I79.0, I79.2, K55.1, K55.8, K55.9, Z95.8, Z95.9, 093.0, 437.3, 440.x, 441.x, 443.1-443.9, 447.1, 557.1, 557.9, V43.4
<b>Cerebrovascular disease</b>	ICD-9: 430.x-438.x ICD-10: G45.x, G46.x, H34
<b>Stroke or Transient ischemic attack</b>	ICD-9: 438.x, V17.1. ICD-10: I60.x, I61.x, I62.x, I63.x, I69.x
<b>COPD</b>	ICD-9: 416.8, 416.9, 490.x-505.x, 506.4, 508.1, 508.8 ICD-10: I27.8, I27.9, J40.x-J47.x, J60.x-J67.x, J68.4, J70.1, J70.3
<b>Chronic kidney disease without dialysis</b>	ICD-9: 403.01, 403.11, 403.91, 404.02, 404.03, 404.12, 404.13, 404.92, 404.93, 582.x, 583.0-583.7, 585.x, 586.x, 588.0, V42.0, V45.1, V56.x ICD-10: I12.0, I13.1, N03.2-N03.7, N05.2-N05.7, N18.x, N19.x, N25.0, Z49.0-Z49.2, Z94.0, Z99.2
<b>Coronary artery disease</b>	ICD-9: 440, 440.1 ICD-10: I70.0, I70.1
<b>Atrial fibrillation</b>	ICD-9: 427.3x ICD-10: I48.91, I48.92

<b>Previous myocardial infarction</b>	ICD-9: 411, 411.1, 412 ICD-10: I24.1, I20.0, I25.2
<b>Congestive heart failure</b>	ICD-9: 398.91, 402.01, 402.11, 402.91, 404.01, 404.03, 404.11, 404.13, 404.91, 404.93, 425.4-425.9, 428.x ICD-10: I09.9, I11.0, I13.0, I13.2, I25.5, I42.0, I42.5-I42.9, I43.x, I50.x, P29.0
<b>Dementia</b>	ICD-9: 290.x, 294.1, 331.2 ICD-10: F00.x-F03.x, F05.1, G30.x, G31.1
<b>Depression</b>	ICD-9: 446.5, 710.0-710.4, 714.0-714.2, 714.8, 725.x ICD-10: M05.x, M06.x, M31.5, M32.x-M34.x, M35.1, M35.3, M36.0
<b>Prior PCI</b>	ICD-9: V4582 ICD-10: Z98.61
<b>Prior CABG</b>	ICD-9: V4581 ICD-10: Z951
<b>POSTOPERATIVE OUTCOMES</b>	
<b>Stroke</b>	ICD-9: 997.02, 431, 432.1, 434.91, 431.11, 434.01 ICD-10: I619, I97811, I97812
<b>Renal failure</b>	ICD-9: 584.x
<b>Cardiac arrest</b>	ICD-9: 4275 ICD-10: I469
<b>Complete heart block</b>	ICD-9: 4260, 42611 ICD-10: I440, I442
<b>Bleeding</b>	ICD-9: 998.1x, 999.8x, 99.01, 99.04, 997.02, 78630, 42989, 5781, 5789, 5780, 7847, 459, 2851, 28659 ICD-10: I97.41x, I97.42, I97.61x, R58, D62, D68311, D68312, D68318, K920, R040, K921, K922, I513, R042, R049
<b>Transfusion with red blood cells</b>	ICD-9: 9900, 9901, 9902, 9903, 9904 ICD-10: 30233N1, 30243N1, 30253N1, 30233H0, 30243H0, 30253H0

CABG – coronary artery bypass graft; CAD – coronary artery disease; CKD – chronic kidney disease; COPD – chronic obstructive pulmonary disease;

PCI – percutaneous coronary intervention

-Most covariates captured by the chronic conditions file; date of onset before date of index admission.

-The following covariates were used for the Charlson score: malignancies, metastatic solid tumor, acquired immune deficiency syndrome, hemi or paraplegia, rheumatic disease, dementia, peptic ulcer disease, Alzheimer's' disease, congestive heart failure, history of myocardial infarction, moderate/severe liver disease, chronic kidney disease, chronic obstructive pulmonary disease, cerebrovascular disease, peripheral vascular disease, diabetes

**eTable 2. Characteristics and outcomes of surgical AVR Patients stratified by 30-day mortality hospital performance ranking**

	<b>Top Performing Group (Lowest 10% Mortality)</b>	<b>Middle Performing Group (Middle 80% Mortality)</b>	<b>Bottom Performing Group (Highest 10% Mortality)</b>	<b>P-Value (Top vs Bottom Group)</b>
<b>Total number of institutions</b>	N=48	N=109	N=34	
<b>Total number of cases</b>	N=2845	N=20478	N=2698	
<b>Characteristics</b>				
Age, (mean, SD)	75.3 (6.6)	76.2 (6.7)	75.9 (6.6)	0.001
≥85yo, (%)	289 (10.2)	2552 (12.5)	308 (11.4)	0.140
Women, (%)	1119 (39.3)	8801 (43.0)	1092 (40.5)	0.395
Dyslipidemia, (%)	2303 (80.9)	16682 (81.5)	2221 (82.3)	0.199
Hypertension, (%)	2430 (85.4)	17957 (87.7)	2407 (89.2)	0.001
Diabetes, (%)	956 (33.6)	7552 (36.9)	1050 (38.9)	0.001
PVD, (%)	22 (0.8)	140 (0.7)	20 (0.7)	1.000
Stroke or TIA, (%)	151 (5.3)	1182 (5.8)	189 (7.0)	0.010
Anemia, (%)	1487 (52.3)	11937 (58.3)	1468 (54.4)	0.112
COPD, (%)	492 (17.3)	3688 (18.0)	600 (22.2)	0.001
Chronic kidney disease, (%)	672 (0.8)	5175 (0.7)	713 (0.7)	0.017
Chronic liver disease, (%)	35 (1.2)	249 (1.2)	27 (1.0)	0.445
Atrial fibrillation, (%)	690 (24.3)	5249 (25.6)	678 (25.1)	0.455
Ischemic heart disease, (%)	2246 (78.9)	16791 (82.0)	2238 (83.0)	0.001
AMI, (%)	56 (2.0)	507 (2.5)	71 (2.6)	0.106
Congestive heart failure, (%)	1346 (47.3)	10853 (53.0)	1313 (48.7)	0.320
Previous PCI, (%)	257 (9.0)	1985 (9.7)	216 (8.0)	0.178
Previous CABG surgery, (%)	177 (6.2)	1464 (7.1)	192 (7.1)	0.196
Charlson score, (Median, IQR)	5 (5-6)	5 (5-6)	5 (5-6)	0.001
<b>Social history</b>				
Alzheimer's, (%)	32 (1.1)	241 (1.2)	38 (1.4)	0.400
Depression, (%)	444 (15.6)	3067 (15.0)	444 (16.5)	0.400
<b>Post-procedure complications</b>				
Bleeding complications, (%)	812 (28.5)	5475 (26.7)	635 (23.5)	0.001
Transfusion, (%)	686 (24.1)	5531 (27.0)	539 (20.0)	0.001

Permanent stroke, (%)	126 (4.4)	776 (3.8)	121 (4.5)	0.948
Acute kidney injury, (%)	318 (11.2)	2358 (11.5)	374 (13.9)	0.003
Permanent pacemaker, (%)	108 (3.8)	1043 (5.1)	140 (5.2)	0.013
Cardiac arrest, (%)	36 (1.3)	348 (1.7)	72 (2.7)	0.001
<b><i>Hospital Disposition</i></b>				
Length of stay, days (Median, IQR)	7 (6-8)	7 (6-8)	7 (6-8)	0.001
Discharge to skilled nursing, (%)	659 (23.2)	6866 (33.5)	879 (32.6)	0.001
30-day mortality, (%)	6 (0.2)	393 (1.9)	145 (5.4)	0.001
Readmission within 30-days, (%)	410 (14.4)	3045 (14.9)	470 (17.4)	0.002
90-day mortality, (%)	31 (1.1)	637 (3.1)	183 (6.8)	0.001
1-year mortality, (%)	121 (4.3)	1254 (6.1)	285 (10.6)	0.001

SD-standard deviation; AVR-aortic valve replacement; PVD-peripheral valvular disease; TIA-transient ischemic attack; COPD-chronic obstructive pulmonary disease; AMI-acute myocardial infarction; PCI-percutaneous coronary intervention; CABG-coronary artery bypass grafting; IQR-interquartile range.

**eTable 3. Characteristics and outcomes of transcatheter AVR patients at hospitals which changed mortality performance rankings from 30-days to 90-days**

	Ranking Improved	Ranking Maintained	Ranking Declined
<b>Total number of institutions</b>	N=19	N=144	N=21
<b>Total number of cases</b>	N=2257	N=26286	N=1686
<b>Characteristics</b>			
Age, (mean, SD)	82.9 (7.5)	82.8 (7.5)	83.4 (7.4)
≥85yo, (%)	1334 (48.9)	11716 (47.7)	1540 (51.0)
Women, (%)	1269 (46.6)	11700 (47.6)	1410 (46.7)
Dyslipidemia, (%)	2375 (87.1)	21625 (88.0)	2662 (88.2)
Hypertension, (%)	2615 (95.9)	23770 (96.7)	2933 (97.2)
Diabetes, (%)	1185 (43.5)	11349 (46.2)	1356 (44.9)
PVD, (%)	19 (0.7)	205 (0.8)	26 (0.9)
Stroke or TIA, (%)	245 (9.0)	2209 (9.0)	306 (10.1)
Anemia, (%)	1916 (70.3)	17642 (71.8)	2178 (72.2)
COPD, (%)	943 (34.6)	8985 (36.5)	1209 (40.1)
Chronic kidney disease, (%)	1417 (0.7)	12632 (0.8)	1587 (0.9)
Chronic liver disease, (%)	54 (2.0)	455 (1.9)	58 (1.9)
Atrial fibrillation, (%)	1008 (37.0)	9452 (38.4)	1226 (40.6)
Ischemic heart disease, (%)	2579 (94.6)	23509 (95.6)	2893 (95.9)
AMI, (%)	166 (6.1)	1446 (5.9)	219 (7.3)
Congestive heart failure, (%)	2316 (85.0)	21420 (87.1)	2617 (86.7)
Previous PCI, (%)	527 (19.3)	4904 (19.9)	568 (18.8)
Previous CABG surgery, (%)	544 (20.0)	4934 (20.1)	607 (20.1)
Charlson score, (Median, IQR)	6 (6-7)	6 (6-7)	6 (6-6.8)
<b>Social history</b>			
Alzheimer's, (%)	73 (2.7)	821 (3.3)	113 (3.7)
Depression, (%)	528 (19.4)	4898 (19.9)	677 (22.4)
<b>Post-procedure complications</b>			
Bleeding complications, (%)	386 (14.9)	4656 (16.9)	265 (15.1)
Transfusion, (%)	337 (14.8)	4600 (15.9)	268 (12.5)
Permanent stroke, (%)	76 (3.6)	810 (3.2)	54 (3.3)
Acute kidney injury, (%)	226 (8.0)	2914 (10.5)	155 (8.4)
Permanent pacemaker, (%)	119 (3.8)	1896 (6.8)	140 (7.8)

Heart block, (%)	12 (0.4)	140 (0.5)	9 (0.7)
Cardiac arrest, (%)	71 (3.0)	650 (2.7)	37 (2.1)
<b>Hospital Disposition</b>			
Length of stay, days (Median, IQR)	5 (4-5)	5 (4-6)	5 (4-5)
Discharge to skilled nursing, (%)	560 (24.0)	7361 (28.3)	466 (25.1)
30-day mortality, (%)	107 (4.8)	1095 (4.5)	61 (2.3)
Readmission within 30-days, (%)	393 (17.4)	4770 (17.9)	302 (19.9)
90-day mortality, (%)	149 (6.0)	2070 (8.0)	160 (11.5)
1-year mortality, (%)	393 (16.7)	4702 (18.4)	329 (20.9)

SD-standard deviation; AVR-aortic valve replacement; PVD-peripheral valvular disease; TIA-transient ischemic attack; COPD-chronic obstructive pulmonary disease; CAD-coronary artery disease; AMI-acute myocardial infarction; PCI-percutaneous coronary intervention; CABG-coronary artery bypass grafting; IQR-interquartile range.

**eTable 4. Characteristics and outcomes of surgical AVR patients at hospitals which changed mortality performance rankings from 30-days to 90-days**

	Ranking Improved	Ranking Maintained	Ranking Declined
<b>Total number of institutions</b>	N=16	N=158	N=17
<b>Total number of cases</b>	N=1261	N=23495	N=1265
<b>Characteristics</b>			
Age, (mean, SD)	74.8 (6.2)	75.6 (6.4)	74.9 (6.4)
≥85yo, (%)	130 (9.1)	2886 (10.6)	133 (8.1)
Women, (%)	511 (39.0)	9973 (41.9)	528 (39.4)
Dyslipidemia, (%)	1015 (77.9)	19194 (79.9)	997 (78.1)
Hypertension, (%)	1110 (87.4)	20602 (86.9)	1082 (85.2)
Diabetes, (%)	463 (34.2)	8629 (36.5)	466 (34.0)
Stroke or TIA, (%)	67 (4.9)	1381 (5.3)	74 (5.5)
Anemia, (%)	697 (51.7)	13506 (54.5)	689 (51.9)
COPD, (%)	243 (19.9)	4317 (19.0)	220 (16.1)
Chronic kidney disease, (%)	293 (0.5)	5942 (0.7)	325 (0.8)
Chronic liver disease, (%)	18 (1.1)	270 (1.2)	23 (1.8)
Atrial fibrillation, (%)	298 (24.1)	6001 (22.9)	318 (24.2)
Ischemic heart disease, (%)	987 (76.5)	19263 (79.7)	1025 (76.2)
AMI, (%)	20 (1.4)	583 (2.6)	31 (2.1)
Congestive heart failure, (%)	569 (44.8)	12357 (50.2)	586 (43.7)
Previous PCI, (%)	101 (8.4)	2263 (8.6)	94 (5.7)
Previous CABG surgery, (%)	89 (6.9)	1669 (6.0)	75 (5.1)
Charlson score, (Median, IQR)	5 (5-5)	5 (5.5)	5 (5-5.3)
<b>Social history</b>			
Alzheimer's, (%)	13 (0.8)	286 (1.1)	12 (0.9)
Depression, (%)	196 (16.3)	3562 (15.3)	197 (15.0)
<b>Post-procedure complications</b>			
Bleeding complications, (%)	418 (28.5)	6234 (22.9)	270 (25.3)
Transfusion, (%)	396 (33.0)	5964 (23.7)	396 (24.8)
Permanent stroke, (%)	58 (5.1)	915 (4.5)	50 (5.6)
Acute kidney injury, (%)	197 (15.0)	2734 (11.7)	119 (10.8)
Permanent pacemaker, (%)	74 (5.2)	1173 (4.7)	44 (4.4)
Heart block, (%)	5 (0.4)	72 (0.3)	1 (0.0)



Cardiac arrest, (%)	35 (2.2)	395 (1.7)	26 (1.8)
<b>Hospital Disposition</b>			
Length of stay, days (Median, IQR)	6.8 (6-8)	7.0 (6-8)	7.0 (6-7.5)
Discharge to skilled nursing, (%)	347 (26.9)	7667 (31.7)	390 (28.3)
30-day mortality, (%)	43 (4.2)	477 (2.4)	24 (1.3)
Readmission within 30-days, (%)	200 (15.9)	3498 (14.4)	227 (15.8)
90-day mortality, (%)	46 (4.4)	743 (3.4)	62 (4.8)
1-year mortality, (%)	97 (7.6)	1458 (6.8)	105 (7.2)

SD-standard deviation; AVR-aortic valve replacement; PVD-peripheral valvular disease; TIA-transient ischemic attack; COPD-chronic obstructive pulmonary disease; CAD-coronary artery disease; AMI-acute myocardial infarction; PCI-percutaneous coronary intervention; CABG-coronary artery bypass grafting; IQR-interquartile range.

**eTable 5: Changes in percentile ranking from 30-day mortality to 90-day mortality through median shift in continuous rank**


		Delta in Percentile Ranking from 30d Mortality to 90d Mortality								
30 day mortality percentile group*		90 day mortality percentile group								
		1	2	3	4	5	6	7	8	9
SAVR	1	46 73.0%	6 9.5%	4 6.3%	3 4.8%	3 4.8%	0 0.0%	1 1.6%		
	2	5 23.8%	5 23.8%	7 33.3%	2 9.5%	2 9.5%	0 0.0%	0 0.0%		
	3	1 3.4%	9 31.0%	5 17.2%	7 24.1%	5 17.2%	1 3.4%	1 3.4%		
	4	0 0.0%	1 4.8%	6 28.6%	6 28.6%	2 9.5%	6 28.6%	0 0.0%		
	5	0 0.0%	0 0.0%	3 12.5%	6 25.0%	7 29.2%	5 20.8%	3 12.5%		
	6	0 0.0%	0 0.0%	0 0.0%	0 0.0%	7 29.2%	11 45.8%	6 25.0%		
	7	0 0.0%	0 0.0%	0 0.0%	0 0.0%	0 0.0%	1 11.1%	8 88.9%		
TAVR	1	13 41.9%	7 22.6%	6 19.4%	1 3.2%	1 3.2%	1 3.2%	0 0.0%	0 0.0%	2 6.5%
	2	6 31.6%	5 26.3%	4 21.1%	2 10.5%	2 10.5%	0 0.0%	0 0.0%	0 0.0%	0 0.0%
	3	2 10.0%	2 10.0%	6 30.0%	4 20.0%	2 10.0%	2 10.0%	0 0.0%	2 10.0%	0 0.0%
	4	0 0.0%	3 12.5%	3 12.5%	5 20.8%	6 25.0%	5 20.8%	2 8.3%	0 0.0%	0 0.0%
	5	1 3.7%	3 11.1%	5 18.5%	7 25.9%	5 18.5%	1 3.7%	5 18.5%	0 0.0%	0 0.0%
	6	0 0.0%	1 4.8%	0 0.0%	3 14.3%	3 14.3%	6 28.6%	5 23.8%	2 9.5%	1 4.8%
	7	0 0.0%	1 5.0%	0 0.0%	3 15.0%	3 5.0%	4 20.0%	4 20.0%	7 35.0%	0 0.0%
	8	0 0.0%	0 0.0%	0 0.0%	0 0.0%	1 5.3%	0 0.0%	4 21.1%	8 42.1%	6 31.6%
	9	0 0.0%	0 0.0%	0 0.0%	0 0.0%	0 0.0%	0 0.0%	1 33.3%	1 66.7%	2 66.7%
Total	1	59 62.8%	13 13.8%	10 10.6%	4 4.3%	4 4.3%	1 1.1%	1 1.1%	0 0.0%	2 2.1%
	2	11 27.5%	10 25.0%	11 27.5%	4 10.0%	4 10.0%	0 0.0%	0 0.0%	0 0.0%	0 0.0%
	3	3 6.1%	11 22.4%	11 22.4%	11 22.4%	7 14.3%	3 6.1%	1 2.0%	2 4.1%	0 0.0%
	4	0 0.0%	4 8.9%	9 20.0%	11 24.4%	8 17.8%	11 24.4%	2 4.4%	0 0.0%	0 0.0%
	5	1 2.0%	3 5.9%	8 15.7%	13 25.5%	12 23.5%	6 11.8%	8 15.7%	0 0.0%	0 0.0%
	6	0 0.0%	1 2.2%	0 0.0%	3 6.7%	10 22.2%	17 37.8%	11 24.4%	2 4.4%	1 2.2%
	7	0 0.0%	1 3.4%	0 0.0%	3 10.3%	3 3.4%	5 17.2%	12 41.4%	7 24.1%	0 0.0%
	8	0 0.0%	0 0.0%	0 0.0%	0 0.0%	1 5.3%	0 0.0%	4 21.1%	8 42.1%	6 31.6%
	9	0 0.0%	0 0.0%	0 0.0%	0 0.0%	0 0.0%	0 0.0%	1 33.3%	1 66.7%	2 66.7%

**Notes:** Each box is not one percentile but rather a range of percentiles that does not coincide exactly with deciles due to the large number of ties in observed mortality percentages across the institutions in this study. Thus, we did not wind up with 10 groups each containing 10% of institutions but 7 percentile categories for TAVR and 9 for SAVR and 9 for overall. **This means that 38% of programs were within +/-6 percentiles of their 30d rankings at 90 days, 36% were within +/-18 percentiles (i.e. institutions at the 50th percentile at 30 days fell between the 32th – 68th percentile at 90 days), 16% decreased rank by >18 percentile, and 10% increased rank by >18 percentiles. Thus, not only were over a quarter of institutions in a clinically meaningful different rank at 90 days from their 30 day baseline, their mortality rankings were more likely to be substantially worse at 90 days, than improved by a ratio of 3:2.**

**eTable 6. Mean postoperative hospital mortality at 90-days and 1-year for transcatheter and surgical AVR stratified by 30-day mortality performance groups**


	N hospitals	N patients	Baseline 30-day Mortality			90-day Mortality			1-year Mortality		
			Mean	95% Confidence Interval		Mean	95% Confidence Interval		Mean	95% Confidence Interval	
				Lower	Upper		Lower	Upper		Lower	Upper
<b>30-day Mortality ranking (TAVR Procedure)</b>	184	30329									
Top Performing Group <i>(Lowest 10% Mortality)</i>	27	2726	0.83	0.80	1.0	5.7	4.3	7.2	14.8	12.5	17.0
Middle Performing Group <i>(Middle 80% Mortality)</i>	130	24585	3.9	3.7	4.1	7.4	7.0	7.8	17.3	16.6	17.9
Bottom Performing Group <i>(Highest 10% Mortality)</i>	27	3018	9.0	7.9	10.1	13.4	11.8	15.0	24.1	21.6	26.7
<b>30-day Mortality ranking (SAVR Procedure)</b>	191	26021									
Top Performing Group <i>(Lowest 10% Mortality)</i>	48	2845	0.04	0.009	0.08	0.7	0.3	1.3	4.5	3.3	5.8
Middle Performing Group <i>(Middle 80% Mortality)</i>	109	20478	2.1	1.9	2.3	3.3	3.1	3.6	6.3	5.9	6.7
Bottom Performing Group <i>(Highest 10% Mortality)</i>	34	2698	5.4	4.9	5.9	6.3	5.5	7.2	10.2	8.9	11.2

**eFigure 1. Study consort diagram.** For each procedure (transcatheter AVR and surgical AVR), hospitals are ranked based on the mean 30-day mortality rate during the 4-year period into 3 groups: (1) Top (lowest 10% mortality rate), (2) Middle (Middle 80% mortality rate), or (3) Bottom (highest 10% mortality) performing groups.




**eFigure 2: Changes in hospital performance rankings at 90-days and 1-year stratified by risk-adjusted 30-day mortality for transcatheter AVR and surgical AVR.** We examine changes in hospital performance ranking at 90-days and 1-year for each of the hospitals originally classified into 3 groups according to their risk-adjusted 30-day mortality rate during the 4-year period: (1) Top (lowest 10% mortality rate), (2) Middle (Middle 80% mortality rate), or (3) Bottom (highest 10% mortality) performing groups.

**Figure: (Adjusted Analysis) Changes in Hospital Performance Rankings at 90-days and 1-year for Transcatheter and Surgical Aortic Valve Replacement**



**eFigure 3: Distribution of causes of death for transcatheter AVR and surgical AVR patients at 30-days, 90-days and 1-year.** Cardiac procedure-related death are defined as heart failure, myocardial infarction, cardiac arrest, death as direct result of cardiac surgery or malfunction of the valve. Cardiac non-procedure related death are defined as a postoperative complication: renal or multi-system organ failure deaths in person w/o preexisting diagnoses of major organ disease, stroke/coma/thromboembolic events, sepsis/postop surgery-related infections, unexpected bleeding/coagulopathy. Non-cardiac causes of death include all other causes such as trauma, accidental death, gunshot wound, suicide, death attributable to pre-existing non-cardiac disease, death after non-cardiac procedure.



**eFigure 4: The hazard (risk of mortality) after both transcatheter AVR and surgical AVR.** Time zero is the day of the procedure. The hazard (risk of mortality) after both procedures continues to decline well after 30 days postoperatively. The constant phase of the hazard seems to start after ~90 days for transcatheter AVR and ~60 days for surgical AVR.

